-+ 0.00%
-+ 0.00%
-+ 0.00%

Kura Oncology To Present Updated Data From FIT-001 Clinical Study Of Darlifarnib In Combination With Cabozantinib

Benzinga·04/09/2026 11:35:19
Listen to the news

Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France.